Veristat Continues To Be Recognized for Its Positive Impact & Company Growth
Today we announced that we have been recognized once again by Inc. Magazine as one of America’s fastest-growing private companies. Veristat debuted on the list in 2015.
“Veristat is proud to have secured its ranking on the Inc. 5000 list for another year.” stated Patrick Flanagan, Chief Executive Officer of Veristat, “It’s an honor to receive this acknowledgement and is proof that Veristat’s passion for helping clients accelerate their life-enhancing and life-saving therapies through the clinical development process is working. I am proud of the entire Veristat team for working so hard to assist clients every day and exhibiting an unwavering commitment to improving people’s lives.”
Veristat was founded over 20 years ago with a core focus in providing pharmaceutical and biotechnology companies with biometrics, medical writing and strategic regulatory consulting services. Over the past decade and particularly over the past 5 years, the company has expanded into a full-service CRO to help clients design, conduct, analyze and submit the results of their clinical studies for regulatory approval. Last year, Veristat doubled the size of its corporate headquarters and opened its first west coast office to serve our long time clients in the San Francisco Bay area.
In 2016, Veristat expanded into Europe and now offers the ability to run clinical trials in North America, Europe, and Australia. Additionally, we continued the expansion of our United States footprint with the opening of a Raleigh-Durham office scheduled for the fourth quarter of 2016. We will continue to grow organically and through acquisition to meet the growing needs and demands of our clients.
Earlier this year, Veristat was recognized as one of the “Top 50 Fastest-Growing Private Companies in Massachusetts” by the Boston Business Journal. Today’s Inc. 5000 ranking is yet another accolade of Veristat from a prestigious organization that measures and endorses the growth of US companies.
Since 1982, Inc. has ranked the fastest-growing private companies in the United States and published the results on its annual 5000 list. The 2016 Inc. 5000 is ranked according to percentage revenue growth when comparing 2012 to 2015. To qualify, companies must have been founded and generating revenue by the first week of the starting calendar year, and therefore able to show four full calendar years of sales. Additionally, they had to be U.S.-based, privately held, and independent—not subsidiaries or divisions of other companies—as of December 31 of the last year measured. To learn more and to view the 2016 Inc. 5000 list visit: http://www.inc.com/inc5000/list/2016/.
Veristat, LLC is an innovative full-service, science-focused clinical research organization (CRO) with over 20 years of experience in supporting clinical trials and regulatory submissions for pharmaceutical, biotechnology, and medical device companies. Veristat offers comprehensive clinical development services, including biostatistics, statistical programming, medical writing, clinical monitoring and data management, for a single study or an entire clinical program, as well as preparation of integrated summary documents and submission-ready CDISC data for regulatory filings. Due to Veristat’s unwavering commitment to scientific integrity, client focus and exceptional performance, long-lasting client relationships are our hallmark. For more information, please visit www.veristat.com.
Gillian Dellacioppa, Marketing Director
Gillian.email@example.com or 508-306-6336